Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Decline in antibody concentration 6 months after two doses of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients and healthy controls

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. High incidence of subclinical peripheral artery disease in people with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Dynamics of a Staphylococcus aureus infective endocarditis simulation model

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. ECG and CT for the detection of left atrial enlargement in hypertensive individuals-a population-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

Background: Previous studies have indicated inferior responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination in solid organ transplant (SOT) recipients. We examined the development of anti-receptor-binding domain (RBD) immunoglobulin G (IgG) after two doses of BNT162b2b in SOT recipients 6 months after vaccination and compared to that of immunocompetent controls.

Methods: We measured anti-RBD IgG after two doses of BNT162b2 in 200 SOT recipients and 200 matched healthy controls up to 6 months after first vaccination. Anti-RBD IgG concentration and neutralizing capacity of antibodies were measured at first and second doses of BNT162b2 and 2 and 6 months after the first dose. T-cell responses were measured 6 months after the first dose.

Results: In SOT recipients, geometric mean concentration (GMC) of anti-RBD IgG increased from first to second dose (1.14 AU/ml, 95% CI 1.08-1.24 to 11.97 AU/ml, 95% CI 7.73-18.77) and from second dose to 2 months (249.29 AU/ml, 95% CI 153.70-385.19). Six months after the first vaccine, anti-RBD IgG declined (55.85 AU/ml, 95% CI 36.95-83.33). At all time points, anti-RBD IgG was lower in SOT recipients than that in controls. Fewer SOT recipients than controls had a cellular response (13.1% vs. 59.4%, p < 0.001). Risk factors associated with humoral non-response included age [relative risk (RR) 1.23 per 10-year increase, 95% CI 1.11-1.35, p < 0.001], being within 1 year from transplantation (RR 1.55, 95% CI 1.30-1.85, p < 0.001), treatment with mycophenolate (RR 1.54, 95% CI 1.09-2.18, p = 0.015), treatment with corticosteroids (RR 1.45, 95% CI 1.10-1.90, p = 0.009), kidney transplantation (RR 1.70, 95% CI 1.25-2.30, p = 0.001), lung transplantation (RR 1.63, 95% CI 1.16-2.29, p = 0.005), and de novo non-skin cancer comorbidity (RR 1.52, 95% CI, 1.26-1.82, p < 0.001).

Conclusion: Immune responses to BNT162b2 are inferior in SOT recipients compared to healthy controls, and studies aiming to determine the clinical impact of inferior vaccine responses are warranted.

OriginalsprogEngelsk
Artikelnummer832501
TidsskriftFrontiers in Immunology
Vol/bind13
Antal sider10
ISSN1664-3224
DOI
StatusUdgivet - 23 feb. 2022

Bibliografisk note

Copyright © 2022 Hamm, Møller, Pérez-Alós, Hansen, Pries-Heje, Heftdal, Hasselbalch, Fogh, Madsen, Almagro Armenteros, Knudsen, Poulsen, Frikke-Schmidt, Hilsted, Sørensen, Ostrowski, Harboe, Perch, Sørensen, Rasmussen, Bundgaard, Garred, Iversen and Nielsen.

ID: 75622624